Dennis Lund Hansen

Summary Corticosteroids remain the first‐line treatment of immune thrombocytopenia (ITP), but increase the risk of osteoporosis and fractures. Bisphosphonates are used for the treatment of osteoporosis, but their usage among patients with ITP has not been systemically described. We investigated the risk of fractures and the use of bisphosphonates in adult patients with primary (pITP) and secondary ITP (sITP) compared with matched comparators in a nationwide registry‐based cohort study. We identified 4030 patients with pITP (median age 60 years [IQR, 40–74]), 550 with sITP (median age 59 years [IQR, 43–74]) and 182 939 age–sex‐matched general population comparators. All individuals were followed for incident fractures. Bisphosphonate use was estimated for calendar‐years and in temporal relation to the ITP diagnosis. Adjusted cause‐specific hazard ratio (csHR) for any fracture was 1.37 (95% confidence interval [CI] 1.23; 1.54) for pITP and 1.54 (1.17; 2.03) for sITP. The first‐year csHR was 1.82 (1.39; 2.40) for pITP and 2.78 (1.58; 4.91) for sITP. Bisphosphonate use over calendar‐years and in the early years following ITP diagnosis was higher among patients with ITP diagnosis compared with the general population. In conclusion, the risk of fractures and the use of bisphosphonates are higher in patients with ITP compared with the general population.